This clinical trial is focused on studying the effects of a new treatment called BI 456906 on individuals who are living with overweight or obesity and also have type 2 diabetes. The treatment is administered as a solution for injection under the skin, known as subcutaneous use. The main goal of the study is to see if BI 456906 can help participants lose weight when combined with a reduced-calorie diet and increased physical activity, compared to a placebo.
The study will last for 76 weeks, during which participants will receive either the BI 456906 treatment or a placebo. Throughout the study, participants will be monitored to assess changes in their body weight and other health indicators. The study aims to determine if the treatment can lead to a significant reduction in body weight and improve other health measures related to type 2 diabetes.
Participants will be evaluated on various outcomes, including the percentage change in body weight and the achievement of specific weight loss goals. The study will also look at changes in waist circumference, blood sugar levels (measured by HbA1c), and other health-related scores. This research is important for understanding how BI 456906 might help people with overweight or obesity and type 2 diabetes manage their weight and improve their overall health.



Belgium
Czechia
Denmark
Finland
Germany
Greece
Hungary
Poland
Spain
Sweden
The Netherlands